Ignite Creation Date:
2025-12-25 @ 2:31 AM
Ignite Modification Date:
2026-06-25 @ 1:08 AM
Study NCT ID:
NCT04638634
Status:
TERMINATED
Last Update Posted:
2021-12-10
First Post:
2020-11-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects
Sponsor:
CSL Behring
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CSL760_1001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None